Piper Sandler reaffirmed its positive stance on Inspire Medical Systems (NYSE:NYSE:INSP), maintaining an Overweight rating with a $260.00 price target. The endorsement comes after a steep 14.15% ...

The global sleep apnea implants market is expected to grow from USD 317.1 million in 2023 to USD 1,158.1 million by 2033, at ...

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Inspire Medical Systems (INSP – Research Report) yesterday and set a price ...

Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Inspire Medical Systems (INSP – Research Report) yesterday and set a price ...

Awareness of sleep apnea and its relatively common and effective treatment has grown over the past three decades.

The Food and Drug Administration (FDA) on Dec. 20 approved the obesity medication Zepbound (tirzepatide) as the first pharmaceutical treatment for moderate-to-severe obstructive sleep apnea (OSA) in ...

Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary ...

Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s ...

Nyxoah, founded by Robert Taub, is led by Olivier Taelman and focuses on the Genio implant, which offers a less intrusive alternative to CPAP and Inspire Therapy. Despite a high burn rate ...

(Getty Images) (NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea in obese adults earlier this month. “This is a major step ...